Floatz logo

Vosaroxin

Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)

University of UlmSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) cohort.

Asset / SponsorPhaseRating
Fludarabine
Sumithira Vasu
Phase 2BB
Gilteritinib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3BB
Cytosin-Arabinosid
Sumithira Vasu
Phase 2BB
Thiotepa
Fred Hutchinson Cancer Center
Phase 2B
Azacitidine
Aptose Biosciences Inc.
Phase 2B

View all 29 →

Same molecule, other indications

Vosaroxin is also rated in:

acute myeloid leukemiaDormant
BB
Indicative ·
66 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
61 / 100
View asset →
leukemiaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →